Content about Anti-diabetic drugs

January 3, 2011

This past year saw a lower-than-usual number of new drugs approved by the Food and Drug Administration, due in part to delays at the agency, according to published reports.

NEW YORK — This past year saw a lower-than-usual number of new drugs approved by the Food and Drug Administration, due in part to delays at the agency, according to published reports.

The Wall Street Journal reported that 21 new drugs were approved through the year, compared with 25 in 2009 and 24 in 2008. The lag came in part due to stricter safety regulations, the newspaper reported.

December 21, 2010

A biopharmaceutical company exclusively will develop and commercialize oral formulations of a drug maker's insulins.

PRINCETON, N.J. — A biopharmaceutical company exclusively will develop and commercialize oral formulations of a drug maker's insulins.

Emisphere will be paid $57.5 million in potential product development and sales milestone payments by Novo Nordisk — of which $5 million dollars will be payable upon signing — as well as royalties on sales. Further financial details of the agreement were not disclosed.

December 20, 2010

Drug maker Amylin Pharmaceuticals has submitted the first of a series of sections of a regulatory approval application for a biotech drug to treat patients with a rare lipid disorder.

SAN DIEGO — Drug maker Amylin Pharmaceuticals has submitted the first of a series of sections of a regulatory approval application for a biotech drug to treat patients with a rare lipid disorder.

December 9, 2010

Combining a diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals controls blood sugar and promotes weight loss more than insulin alone, according to a new study.

CHAPEL HILL, N.C. — Combining a diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals controls blood sugar and promotes weight loss more than insulin alone, according to a new study.

December 7, 2010

Supplier News — Fera Pharmaceuticals has recently launched two new topical ointments. The New York-based company has developed Ilotycin (erythromycin) and Garamycin (gentamicin) ophthalmic ointments, both for the treatment of bacterial infections of the eye. “Our goal is simple: to keep more quality healthcare choices alive for the people who need them,” company co-founder Frank DellaFera said.


December 2, 2010

A growing drug-treated population will cause the Type 2 diabetes drug market in China to increase to $2.5 billion by 2014 ...

BURLINGTON, Mass. — A growing drug-treated population will cause the Type 2 diabetes drug market in China to increase to $2.5 billion by 2014, according to a new report by Decision Resources.

The Type 2 diabetes market in China totaled $1.4 billion in 2009, Decision Resources said.

December 2, 2010

Merck announced on Thursday it has inked a deal to acquire an insulin maker.

WHITEHOUSE STATION, N.J., and BEVERLY, Mass. (Dec. 2) Merck announced on Thursday it has inked a deal to acquire an insulin maker.

November 17, 2010

A Type 2 diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals may lower the...

CHICAGO — A Type 2 diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals may lower the risk of cardiovascular disease compared with other diabetes treatments, the two companies said Wednesday.

 

According to a study presented at the American Heart Association’s scientific sessions in Chicago, use of Byetta (exenatide) was associated with a lower incidence of cardiovascular disease than insulin and several other drug classes.

 

 

November 15, 2010

A leading charitable funder of and advocate for Type 1 diabetes research and a drug...

NEW YORK and SAN DIEGO — A leading charitable funder of and advocate for Type 1 diabetes research and a drug maker have entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of an analog of the human hormone leptin in patients with Type 1 diabetes.

November 7, 2010

The Food and Drug Administration approved the first and only once-a-day metformin extended-release plus dipeptidyl...

November 7, 2010

A new study conducted by University of Toronto researchers found that GLP-1 analogues not only...

MISSISSAUGA, Ontario A new study conducted by University of Toronto researchers found that GLP-1 analogues not only help to lower blood-glucose levels, but also have the added benefit of reducing body mass index and waist circumference.

November 2, 2010

The Food and Drug Administration has turned down an application for an insulin product made...

DANBURY, Conn. The Food and Drug Administration has turned down an application for an insulin product made by Biodel, Biodel said.

 

The drug maker announced that it received a complete response letter from the FDA for Linjeta (human insulin [rDNA origin]) for the treatment of Type 1 and Type 2 diabetes.

 

 

November 2, 2010

The CEO of drug maker Eli Lilly has called for a “wave of invention” to...

CLEVELAND The CEO of drug maker Eli Lilly has called for a “wave of invention” to combat diabetes.

Speaking at the Cleveland Clinic Medical Innovation Summit, John Lechleiter said breakthroughs against the disease are needed as urgently today as a century ago, noting that the disease could create a “health and economic time bomb,” as 1-in-3 Americans are forecasted to have the disease by 2050.

 

October 31, 2010

Supermarket chain Stater Bros. will mark National Diabetes Awareness Month by offering free diabetes drugs...

October 27, 2010

An insurance company and a patient assistance program have joined forces to improve medication adherence...

BLOOMFIELD, Conn. An insurance company and a patient assistance program have joined forces to improve medication adherence outcomes of Type 2 diabetes patients.

October 27, 2010

Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug...

BURLINGTON, Mass. Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug from Merck’s Januvia (sitagliptin) and Janumet (sitagliptin and metformin), according to a new report by market research firm Decision Resources.

 

October 24, 2010

Speculation has emerged that Eli Lilly may seek to acquire several other companies in light...

NEW YORK Speculation has emerged that Eli Lilly may seek to acquire several other companies in light of its difficulties winning approval for a long-acting diabetes treatment, according to published reports.

 

October 19, 2010

The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli...

INDIANAPOLIS The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli Lilly and two other companies, the companies said Tuesday.

Lilly, Amylin Pharmaceuticals and Alkermes said the FDA issued them a complete response letter for their application for Bydureon (exenatide), a once-weekly version of the Type 2 diabetes drug Byetta. A complete response letter means that the FDA has completed review of a regulatory application, but issues remain that preclude approval.

 

October 17, 2010

Pfizer has entered the world of biosimilars through a deal with India-based Biocon to distribute...

NEW YORK Pfizer has entered the world of biosimilars through a deal with India-based Biocon to distribute versions of insulin and insulin analog products around the world, the companies said Monday.

 

September 30, 2010

UltiMed, a company that makes insulin-delivery devices, has named a new executive....

ST. PAUL, Minn. UltiMed, a company that makes insulin-delivery devices, has named a new executive.

 

The company announced the appointment of Brahim Zabeli as VP diabetes care for the U.S. market. In the new role, Zabeli will manage commercial activity, including sales, marketing and customer service.

 

 

Zabeli previously worked as director of trade and managed markets for medical supply company Becton, Dickinson & Co.

 

September 23, 2010

An investigational diabetes drug works as well as a generic already on the market, according...

STOCKHOLM An investigational diabetes drug works as well as a generic already on the market, according to results of a late-stage clinical trial announced Friday by AstraZeneca and Bristol-Myers Squibb.

 

September 22, 2010

The Food and Drug Administration has moved to significantly restrict access to a controversial diabetes...

SILVER SPRING, Md. The Food and Drug Administration has moved to significantly restrict access to a controversial diabetes drug made by GlaxoSmithKline.

The agency said Thursday that it would restrict access to the Type 2 diabetes medication Avandia (rosiglitazone) in response to clinical study data suggesting that its use can increase the risk of heart attacks and strokes.

September 19, 2010

An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar...

PARIS An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar in patients with Type 2 diabetes when added to oral diabetes drugs, according to a study presented at a medical conference in Sweden.

September 19, 2010

An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control...

PARIS An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control in patients with diabetes, according to results of a late-stage clinical trial presented at a scientific meeting.

August 31, 2010

A specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes...